133 related articles for article (PubMed ID: 17501698)
1. Emerging therapies for colorectal cancer.
Hezel AF; Ryan DP
Expert Opin Investig Drugs; 2007 Jun; 16(6):867-76. PubMed ID: 17501698
[TBL] [Abstract][Full Text] [Related]
2. Involvement of PI3K/Akt pathway in prostate cancer--potential strategies for developing targeted therapies.
Pommery N; Hénichart JP
Mini Rev Med Chem; 2005 Dec; 5(12):1125-32. PubMed ID: 16375758
[TBL] [Abstract][Full Text] [Related]
3. New approaches and targets in advanced colorectal cancer.
Macarulla T; Capdevila J; Perez-Garcia J; Ramos FJ; Elez ME; Markman B; Ruiz-Echarri M; Tabernero J
Eur J Cancer; 2009 Sep; 45 Suppl 1():79-88. PubMed ID: 19775607
[No Abstract] [Full Text] [Related]
4. Novel targets for anticancer treatment development in colorectal cancer.
Macarulla T; Ramos FJ; Capdevila J; Saura C; Tabernero J
Clin Colorectal Cancer; 2006 Nov; 6(4):265-72. PubMed ID: 17241511
[TBL] [Abstract][Full Text] [Related]
5. PI3 kinase, mTOR, and AKT pathways.
Ramalingam SS; Khuri FR
J Thorac Oncol; 2009 Nov; 4(11 Suppl 3):S1059-60. PubMed ID: 19861916
[No Abstract] [Full Text] [Related]
6. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
7. BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells.
Goulielmaki M; Koustas E; Moysidou E; Vlassi M; Sasazuki T; Shirasawa S; Zografos G; Oikonomou E; Pintzas A
Oncotarget; 2016 Feb; 7(8):9188-221. PubMed ID: 26802026
[TBL] [Abstract][Full Text] [Related]
8. Probing the PI3K/Akt/mTor pathway using
Phyu SM; Tseng CC; Fleming IN; Smith TA
Sci Rep; 2016 Nov; 6():36544. PubMed ID: 27811956
[TBL] [Abstract][Full Text] [Related]
9. Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways.
Pandurangan AK
Asian Pac J Cancer Prev; 2013; 14(4):2201-5. PubMed ID: 23725112
[TBL] [Abstract][Full Text] [Related]
10. The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress.
Bahrami A; Khazaei M; Shahidsales S; Hassanian SM; Hasanzadeh M; Maftouh M; Ferns GA; Avan A
J Cell Biochem; 2018 Jan; 119(1):213-222. PubMed ID: 28513879
[TBL] [Abstract][Full Text] [Related]
11. American Association for Cancer Research 98th Annual Meeting. Anticancer agents - Part III.
Sovran L
IDrugs; 2007 Jun; 10(6):362-5. PubMed ID: 17641995
[No Abstract] [Full Text] [Related]
12. The promise of mTOR inhibitors in the treatment of colorectal cancer.
Kim DD; Eng C
Expert Opin Investig Drugs; 2012 Dec; 21(12):1775-88. PubMed ID: 22978346
[TBL] [Abstract][Full Text] [Related]
13. [PI3K-AKT-mTOR pathway inhibitors].
Cortot A; Armand JP; Soria JC
Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
[TBL] [Abstract][Full Text] [Related]
14. American Association for Cancer Research--99th Annual Meeting. Clinical and preclinical data on promising therapeutics.
Karger GA; Lee W
IDrugs; 2008 Jun; 11(6):415-7. PubMed ID: 18509781
[No Abstract] [Full Text] [Related]
15. Novel agents in the era of targeted therapy: what have we learned and how has our practice changed?
Baselga J
Ann Oncol; 2008 Sep; 19 Suppl 7():vii281-8. PubMed ID: 18790967
[No Abstract] [Full Text] [Related]
16. Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer.
Sathe A; Nawroth R
Methods Mol Biol; 2018; 1655():335-350. PubMed ID: 28889395
[TBL] [Abstract][Full Text] [Related]
17. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma.
Li X; Wu C; Chen N; Gu H; Yen A; Cao L; Wang E; Wang L
Oncotarget; 2016 May; 7(22):33440-50. PubMed ID: 26967052
[TBL] [Abstract][Full Text] [Related]
18. Ultraviolet irradiation activates PI 3-kinase/AKT survival pathway via EGF receptors in human skin in vivo.
Wan YS; Wang ZQ; Shao Y; Voorhees JJ; Fisher GJ
Int J Oncol; 2001 Mar; 18(3):461-6. PubMed ID: 11179472
[TBL] [Abstract][Full Text] [Related]
19. Novel therapeutic approaches in chondrosarcoma.
Polychronidou G; Karavasilis V; Pollack SM; Huang PH; Lee A; Jones RL
Future Oncol; 2017 Mar; 13(7):637-648. PubMed ID: 28133974
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
